Kevzara
Top Ten most popular articles on Pharmafile.com this week
September 29, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, EMA, FDA, HIV, J&J, JJ, Kevzara, Mylan, NICE, Sanofi, nash, top ten
It’s Friday, and it’s time for another round up of the most popular articles on pharmafile.com over the last seven …
Sanofi’s arthritis treatment Kevzara secures NICE recommendation
September 25, 2017Sales and Marketing Kevzara, NICE, Sanofi, pharma, pharmaceutical, rheumatoid arthritis, sarilumab
Sanofi, along with its speciality care global business unit Sanofi Genzyme, are celebrating the news that NICE has passed its …
New potential blockbuster RA treatment enters European market
June 27, 2017Sales and Marketing AbbVie, Humria, Kevzara, Regeneron, Sanofi
The world’s biggest selling drug, AbbVie’s Humira with $16 billion in sales last year, has a new rival in the …
Sanofi and Regeneron score FDA approval for arthritis
May 23, 2017Manufacturing and Production, Sales and Marketing FDA, Kevzara, arthritis, sarilumab
The FDA has awarded Sanofi and Regeneron’s Kevzara (sarilumab) approval for the treatment of moderate to severely active rheumatoid arthritis …
EU recommendation for Sanofi and Regeneron’s arthritis treatment
April 24, 2017Sales and Marketing Kevzara, NICE, sarilumab
Sanofi and Regeneron are celebrating the news that their treatment Kevzara (sarilumab) has received a positive opinion from the EMA’s …
Sanofi & Regeneron’s arthritis drug scores first approval following FDA rejection
February 1, 2017Research and Development, Sales and Marketing Actemra, Humira, Kevzara, Regeneron, Roche, Sanofi, sarilumab
Kevzara (sarilumab), a interleukin-6 (IL06) receptor antibody developed by Sanofi and Regeneron and the first real competitor to Roche’s Actemra …
Latest content
Five Facts about cardiovascular disease
